Targeted RNA Sequencing of Formalin-Fixed, Paraffin-Embedded Temporal Arteries From Giant Cell Arteritis Cases Reveals Viral Signatures
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received April 20, 2021
- Accepted in final form June 28, 2021
- First Published September 7, 2021.
Author Disclosures
- Andrew N. Bubak, PhD (andrew.bubak{at}cuanschutz.edu),
- Teresa Mescher, BS (teresa.mescher{at}cuanschutz.edu),
- Michael Mariani, PhD (michael.mariani{at}uvm.edu),
- Seth E. Frietze, PhD (seth.frietze{at}med.uvm.edu),
- James E. Hassell Jr, PhD (james.hasselljr{at}cuanschutz.edu),
- Christy S. Niemeyer, PhD (christy.niemeyer{at}cuanschutz.edu),
- Christina N. Como, BA (christina.como{at}cuanschutz.edu),
- Anna M. Burnet, BS (anna.burnet{at}cuanschutz.edu),
- Prem S. Subramanian, MD, PhD (prem.subramanian{at}cuanschutz.edu),
- Randall J. Cohrs, PhD (randall.cohrs{at}cuanschutz.edu),
- Ravi Mahalingam, PhD (ravi.mahalingam{at}cuanschutz.edu) and
- Maria A. Nagel, MD
- Andrew N. Bubak, PhD (andrew.bubak{at}cuanschutz.edu),
NONE
NONE
NONE
NONE
ÂNeurokinin-1 receptor antagonists for the treatment of alphaherpesvirusesÂ, United States Patent, 2848-295-PROV.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Teresa Mescher, BS (teresa.mescher{at}cuanschutz.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michael Mariani, PhD (michael.mariani{at}uvm.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Seth E. Frietze, PhD (seth.frietze{at}med.uvm.edu),
NONE
NONE
NONE
(1) International Journal of Molecular Sciences, editorial advisory board member, 2 years (2) Life, editorial advisory board member, <1 year (3) BioMedInformatics, editorial advisory board member, <1 year
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)NIH, P01CA240685, PI, 2021-2025 (2)NSF, OIA-1736097, co-PI, 2017-2022 (3)NIH, R01CA230618, PI, 2017-2022 (4)NIH, R01AI127709, PI, 2017-2022 (5)NIH, R01GM129338-01, PI, 2018-2023 (6)NIH, P01AG0325958-11, subaward, 2019-2024
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- James E. Hassell Jr, PhD (james.hasselljr{at}cuanschutz.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christy S. Niemeyer, PhD (christy.niemeyer{at}cuanschutz.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christina N. Como, BA (christina.como{at}cuanschutz.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anna M. Burnet, BS (anna.burnet{at}cuanschutz.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Prem S. Subramanian, MD, PhD (prem.subramanian{at}cuanschutz.edu),
(1) Horizon Therapeutics
NONE
NONE
(1) Journal of Neuro-Ophthalmology, Digital content editor, 2010-present (2) Journal of AAPOS, associate editor, 2017-present (3) Graefes Archive for Experimental Ophthalmology, editorial board member, 2015-present (4) British Journal of Ophthalmology, section editor, 2011-present (5) Indian Journal of Ophthalmology, advisory board member, 2017-present (6) Orbit, editorial board member, 2021-present (7) Frontiers in Ophthalmology, editorial board member, 2021-present
(1) Use of prostaglandin analogues to lower intracranial pressure by nasal application
(1) Walsh and Hoyt's Essentials of Clinical Neuro-Ophthalmology, 4th ed, Wolters Kluwer, 2021 (2) Ophthalmology in Extreme Environments, Springer Verlag, 2017.
NONE
(1) Horizon Therapeutics (2) GenSight Biologics (3) Invex Therapeutics
NONE
NONE
NONE
(1) Horizon Therapeutics (2) GenSight Biologics (3) Santhera Pharmaceuticals
(1) National Institutes of Health
NONE
(1) Research to Prevent Blindness, USA
NONE
NONE
NONE
NONE
NONE
(1) Expert witness testimony, various plaintiff and defense attorneys
- Randall J. Cohrs, PhD (randall.cohrs{at}cuanschutz.edu),
NONE
NONE
NONE
New Horizons in Translational Medicine, Deputy Editor-in- Chief, 2015
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) NIH P01 AG032958, Project Leader - Project 2, 03/01/09- 12/31/23 (2) 5 R01 NS093716, Principal Investigator, 07/01/15 Â 06/30/21 (3) 1 R01 AI 151290, Principal Investigator, 11/17/20 Â 10/31/25
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ravi Mahalingam, PhD (ravi.mahalingam{at}cuanschutz.edu) and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maria A. Nagel, MD
(1) Zoster Eye Disease Study (ZEDS), National Eye Institute, National Institutes of Health, Member, Data Safety Monitoring Committee
NONE
NONE
(1) Journal of Neurovirology, Editorial Board (Associate Editor), 2015-present
(1) Neurokinin-1 receptor antagonists for the treatment of alphaherpesviruses, United State Patent 2848-295-PROV.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) NIH/NIA P01 AG032958, Co-Project Leader, Project 1, 03/01/2009-12/31/2023; (2) NIH/NINDS R01 NS093716, Co-investigator, 07/01/2015- 06/30/2021; (3) NIH/NIDCD R01 DC00566, Co-investigator, 05/01/2020- 04/30/2021 (4) NIH/NIDCD R01 DC014253, Co-investigator, 08/01/2019- 07/30/21 (5) NIH R01 NS094758, Principal Investigator, 09/01/15- 08/31/20
(1) SPARK/REACH Program, University of Colorado Anschutz Medical Campus, Principal Investigator, 09/01/2020-08/31/2022
NONE
NONE
NONE
NONE
NONE
NONE
(1) Merck (Venable LLP), written report, expert witness
- From the Department of Neurology (A.N.B., T.M., J.E.H., C.S.N., C.N.C., A.M.B., P.S.S., R.J.C., R.M., M.A.N.), University of Colorado School of Medicine, Aurora; Department of Medical Laboratory Sciences (M.M., S.E.F.), University of Vermont, Burlington; Department of Ophthalmology (P.S.S., M.A.N.), University of Colorado School of Medicine, Aurora; Department of Neurosurgery (P.S.S.), University of Colorado School of Medicine, Aurora; and Department of Immunology and Microbiology (R.J.C.), University of Colorado School of Medicine, Aurora.
- Correspondence
Dr. Nagel maria.nagel{at}ucdenver.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Clinical and Ethical Challenges
The challenging patient with varicella-zoster virus diseaseMaria A. Nagel, Don Gilden et al.Neurology: Clinical Practice, April 15, 2013 -
Article
Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritisDon Gilden, Teresa White, Nelly Khmeleva et al.Neurology, February 18, 2015 -
Articles
Varicella zoster virus vasculopathyAnalysis of virus-infected arteriesM.A. Nagel, I. Traktinskiy, Y. Azarkh et al.Neurology, July 13, 2011 -
Article
Multifocal VZV vasculopathy with temporal artery infection mimics giant cell arteritisMaria A. Nagel, Jeffrey L. Bennett, Nelly Khmeleva et al.Neurology, May 01, 2013